Bionomics Investor Presentation Deck

E Focused CNS Pipeline with Multiple Potential Catalysts on the Horizon PROGRAM BNC210 a7 receptor NAM EmpathBio MERCK COLLABORATION a7 receptor PAM PAIN Nav1.7/1.8 Inhibitors COGNITION Kv3.1/3.2 Activators Bionomics PRECLINICAL Social Anxiety Disorder (SAD) 150 patients across 15-20 centers in US Post-Traumatic Stress Disorder (PTSD) 200 patients across ~25 centers in US +MDMA derivative EMP-01 (PTSD) 2 candidates for cognitive deficits in Alzheimer's disease Candidate PHASE 1 Series Lead NAM = Negative Allosteric Modulator PAM = Positive Allosteric Modulator PHASE 2 PREVAIL Study ATTUNE Study Memorandum of Understanding to explore combination treatment regimen for PTSD Fast Track Designation Fast Track Designation PHASE 3 EXPECTED TIMING Study underway Topline Data: YE'22 Study underway Topline Data: 1H'23 Ongoing Phase 1 safety & biomarker studies ongoing Ongoing 4

View entire presentation